Banco Santander S.A. Purchases Shares of 40,000 Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Banco Santander S.A. acquired a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNYGet Rating) in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 40,000 shares of the biopharmaceutical company’s stock, valued at approximately $6,532,000.

A number of other institutional investors have also recently made changes to their positions in the business. Brown Advisory Inc. grew its holdings in Alnylam Pharmaceuticals by 57.0% during the 1st quarter. Brown Advisory Inc. now owns 41,727 shares of the biopharmaceutical company’s stock worth $6,814,000 after acquiring an additional 15,149 shares in the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. grew its holdings in Alnylam Pharmaceuticals by 6.5% during the 1st quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 31,637 shares of the biopharmaceutical company’s stock worth $5,166,000 after acquiring an additional 1,918 shares in the last quarter. M&T Bank Corp lifted its position in shares of Alnylam Pharmaceuticals by 30.0% during the 1st quarter. M&T Bank Corp now owns 4,662 shares of the biopharmaceutical company’s stock worth $763,000 after buying an additional 1,075 shares during the last quarter. Qube Research & Technologies Ltd lifted its position in shares of Alnylam Pharmaceuticals by 97.1% during the 1st quarter. Qube Research & Technologies Ltd now owns 6,951 shares of the biopharmaceutical company’s stock worth $1,135,000 after buying an additional 3,424 shares during the last quarter. Finally, Sector Gamma AS purchased a new stake in shares of Alnylam Pharmaceuticals during the 1st quarter worth approximately $9,675,000. Institutional investors and hedge funds own 92.39% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on ALNY shares. SVB Leerink boosted their price objective on shares of Alnylam Pharmaceuticals from $96.00 to $98.00 and gave the stock a “market perform” rating in a research report on Wednesday, June 15th. BMO Capital Markets boosted their price objective on shares of Alnylam Pharmaceuticals from $166.00 to $192.00 and gave the stock a “market perform” rating in a research report on Thursday. Citigroup boosted their price objective on shares of Alnylam Pharmaceuticals from $206.00 to $280.00 in a research report on Thursday. Guggenheim downgraded shares of Alnylam Pharmaceuticals from a “buy” rating to a “neutral” rating in a research report on Monday, June 27th. Finally, William Blair began coverage on shares of Alnylam Pharmaceuticals in a research report on Tuesday, June 7th. They issued an “outperform” rating for the company. Six equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $225.75.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other news, EVP Tolga Tanguler sold 1,754 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Tuesday, July 5th. The shares were sold at an average price of $150.00, for a total transaction of $263,100.00. Following the sale, the executive vice president now owns 1,754 shares in the company, valued at $263,100. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold a total of 5,349 shares of company stock valued at $1,033,073 over the last ninety days. Corporate insiders own 1.40% of the company’s stock.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY opened at $218.58 on Friday. The company has a 50-day simple moving average of $145.22 and a 200-day simple moving average of $147.90. The company has a quick ratio of 3.62, a current ratio of 3.76 and a debt-to-equity ratio of 3.85. The company has a market capitalization of $26.24 billion, a PE ratio of -26.75 and a beta of 0.74. Alnylam Pharmaceuticals, Inc. has a 52-week low of $117.58 and a 52-week high of $226.00.

Alnylam Pharmaceuticals (NASDAQ:ALNYGet Rating) last posted its earnings results on Thursday, July 28th. The biopharmaceutical company reported ($2.29) earnings per share for the quarter, missing the consensus estimate of ($1.62) by ($0.67). The business had revenue of $224.80 million for the quarter, compared to analysts’ expectations of $256.06 million. Alnylam Pharmaceuticals had a negative net margin of 110.91% and a negative return on equity of 204.18%. The business’s revenue was up 1.9% compared to the same quarter last year. During the same quarter last year, the business posted ($1.61) earnings per share. Equities research analysts predict that Alnylam Pharmaceuticals, Inc. will post -7.86 earnings per share for the current fiscal year.

Alnylam Pharmaceuticals Company Profile

(Get Rating)

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases.

Featured Stories

Institutional Ownership by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.